Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217063 | 1.00 | SPPL2A (0.59) | SPPL2A | |
| SCHEMBL8228349 | 1.00 | SPPL2A (0.59) | SPPL2A | |
| SCHEMBL14602751 | 0.94 | SPPL2A (0.58) | SPPL2A | |
| SCHEMBL12757909 | 0.94 | SPPL2A (0.58) | SPPL2A | |
| SCHEMBL14602750 | 0.94 | SPPL2A (0.58) | SPPL2A | |
| SCHEMBL12757911 | 0.94 | SPPL2A (0.58) | SPPL2A | |
| SCHEMBL13538161 | 0.92 | SPPL2A (0.52) | SPPL2A | |
| SCHEMBL13538238 | 0.91 | SPPL2A (0.49) | SPPL2A | |
| SCHEMBL13537646 | 0.91 | — | — | |
| SCHEMBL8222588 | 0.91 | SPPL2A (0.49) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304129-A | Azaalkanone derivative or pharmaceutically acceptable salt thereof, preparation method and application thereof, and pharmaceutical composition | 中国医学科学院医药生物技术研究所 | 2023-12-29 | — | — | CN | disclosed |
| US-9487541-B2 | Fused tricyclic ether carbamates and their use | PURDUE RESEARCH FOUNDATION (US) | 2016-11-08 | — | — | US | disclosed |
| US-9309213-B2 | C-3 substituted bicyclooctane based HIV protease inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9085571-B2 | Nonpeptide HIV-1 protease inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140315946-A1 | NONPEPTIDE HIV-1 PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2014-10-23 | — | — | US | disclosed |
| US-8791135-B2 | Nonpeptide HIV-1 protease inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140179754-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140148508-A1 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| US-8563597-B2 | Fused tricyclic ether carbamates and their use | PURDUE RESEARCH FOUNDATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-8501961-B2 | HIV protease inhibitors and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2013-08-06 | — | — | US | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1937655-A1 | HIV-1 PROTEASE INHIBITORS, AND METHODS OF MAKING AND USING THEM | University of Massachusetts (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007002173-A1 | HIV-1 PROTEASE INHIBITORS, AND METHODS OF MAKING AND USING THEM | UNIVERSITY OF MASSACHUSETTS (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | SPPL2A 181/4885 |
| US-20140315946-A1 | NONPEPTIDE HIV-1 PROTEASE INHIBITORS | DNPEP, PRSS1, SERPINB1 | SPPL2A 354/4885 |
| US-20140148508-A1 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS | CTRC, C9, CTSC | SPPL2A 1011/4885 |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | SPPL2A 181/4885 |
| US-20140179754-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | CTSE, DNPEP, CTSS | SPPL2A 2177/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | SPPL2A 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.